OakChart

Milestone Pharmaceuticals Inc

MISTHealthcare·Biotechnology·Canada·Micro·NASD·Nov 11 • 12:55 PM ET

0.6650+0.0028 (0.42%)
2026-11-11 18:55 CET
Market cap
82.44 USD m
Revenue, TTM
2.34 USD m
Net income, TTM
-84.01 USD m
Free cash flow, TTM
-61.10 USD m
EPS diluted, TTM
-0.69
P/E
-
Compare

Price

MIST against its 20, 50 and 200-day averages
2050200missearnings
1.001.502.002.9M5.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MISTclose 0.6720-day 0.7250-day 0.83200-day 1.320.67

78.3% under the 52-week high of 3.06 on 12 Dec 2025. 52-week low 0.63 on 26 Oct 2026. Last 15 sessions, 32.5% high to low

Profile

MIST
52-week range, 1% of the way up
0.633.06

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Employees38
IPOMay 09, 2019
Beta1.08
ATR, 14d0.06
Rel volume2.53
Short float16.29%
Insider own1.92%
Inst own39.83%

Snapshot

6 groups

Valuation

Index-
Market Cap82.79M
Enterprise Value54.01M
Income-84.01M
Sales2.34M
Book/sh0.15
Cash/sh1.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees38
IPOMay 09, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S35.38
P/B4.54
P/C0.49
P/FCF-
EV/EBITDA-
EV/Sales23.08
Quick Ratio7.92
Current Ratio8.13
Debt/Eq7.78
LT Debt/Eq7.75
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.69
EPS next Y-0.80
EPS next Q-0.22
EPS this Y-12.57%
EPS next Y4.74%
EPS next 5Y24.87%
EPS past 3/5Y18.24% 15.09%
Sales past 3/5Y-32.38% -
EPS Y/Y TTM21.42%
Sales Y/Y TTM-
EPS Q/Q-5.63%
Sales Q/Q-
EarningsNov 13 BMO
EPS/Sales Surpr.-7.69% -31.55%

Ownership

Insider Own1.92%
Insider Trans0.00%
Inst Own39.83%
Inst Trans8.55%
ROA-73.36%
ROE-35522.62%
ROIC-52.71%
Gross Margin90.70%
Oper. Margin-3360.86%
Profit Margin-3585.62%
SMA20-7.33%
SMA50-19.49%
SMA200-49.73%
Trades-

Technical

Shs Outstand124.50M
Shs Float122.10M
Short Float16.29%
Short Ratio14.63
Short Interest19.90M
52W High3.06 -78.27%
52W Low0.63 5.44%
Volatility10.88% 8.98%
ATR (14)0.06
RSI (14)41.05
Beta1.08
Rel Volume2.53
Avg Volume1.36M
Volume1,891,674

Performance

Perf Week-13.92%
Perf Month-13.16%
Perf Quarter-37.85%
Perf Half Y-61.34%
Perf YTD-67.08%
Perf Year-65.18%
Perf 3Y-77.15%
Perf 5Y-88.12%
Perf 10Y-
Recom1.29
Target Price5.57
Prev Close0.66
Price0.67
Change %0.42%

Analyst ratings

latest 10 of 18
DateActionAnalystRating changeTargetImplied
Aug 20, 2026InitiatedCCantor FitzgeraldOverweight$3+351.1%
Apr 10, 2026InitiatedRRaymond JamesStrong Buy$6+802.3%
Dec 15, 2025UpgradeTTD CowenHold → Buy$8+1,103.0%
Sep 11, 2025InitiatedWWells FargoOverweight$4+501.5%
Jun 05, 2025ResumedHH.C. WainwrightBuy$5+651.9%
Aug 22, 2024InitiatedRRodman & RenshawBuy$9+1,253.4%
Jun 20, 2023DowngradeJJefferiesBuy → Hold$8 → $4+501.5%
Apr 22, 2022UpgradePPiper SandlerNeutral → Overweight$8 → $10+1,403.8%
Mar 05, 2021InitiatedHH.C. WainwrightBuy$20+2,907.5%
Jul 29, 2020UpgradeOOppenheimerPerform → Outperform$18+2,606.8%

Peers

Mkt cap
TickerCompanyMkt cap
TENXTenax Therapeutics Inc77.19M
LXRXLexicon Pharmaceuticals Inc839.27M
MLYSMineralys Therapeutics Inc1.39B
HRTXHeron Therapeutics Inc66.54M
TNYATenaya Therapeutics Inc86.70M
ARDXArdelyx Inc780.51M
VNDAVanda Pharmaceuticals Inc250.05M
CYTKCytokinetics Inc8.15B
CVKDCadrenal Therapeutics Inc4.92M
KARDKardigan Inc1.46B

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Oliveto JosephPresident and CEOApr 16 '26Sale2.2636,50082,490446,244Apr 20 04:06 PM
JOSEPH OLIVETODirectorApr 16 '26Proposed Sale2.2036,50080,300Apr 16 04:12 PM
Bharucha DavidChief Medical OfficerDec 15 '25Sale2.3258,007134,576105,326Jan 28 06:30 PM
Bharucha DavidChief Medical OfficerJan 26 '26Sale1.9312,24523,633113,181Jan 28 06:30 PM
Nelson Jeffrey EdwardChief Operating OfficerDec 15 '25Sale2.3258,007134,57641,993Jan 28 06:30 PM
Nelson Jeffrey EdwardChief Operating OfficerJan 26 '26Sale1.9312,24523,63349,848Jan 28 06:30 PM
Muller LorenzChief Commercial OfficerDec 15 '25Sale2.3253,566124,273196,486Jan 28 06:30 PM
Muller LorenzChief Commercial OfficerJan 26 '26Sale1.9311,18021,577205,406Jan 28 06:30 PM
Hasija AmitCFO & EVP of Corp. DevelopmentDec 15 '25Sale2.3258,007134,57691,993Jan 28 06:30 PM
Hasija AmitCFO & EVP of Corp. DevelopmentJan 26 '26Sale1.9312,24523,63399,848Jan 28 06:30 PM
Oliveto JosephPresident and CEODec 15 '25Sale2.32133,054308,685450,667Jan 28 06:30 PM
Oliveto JosephPresident and CEOJan 26 '26Sale1.9334,52366,629482,744Jan 28 06:30 PM
Oliveto JosephPresident and CEOJan 08 '26Sale2.2543,00096,750303,721Jan 09 04:53 PM
Oliveto JosephPresident and CEOJan 07 '26Sale2.255001,125346,721Jan 09 04:53 PM

Held by

AUM
TickerCompanyAUM
SURISimplify Propel Opportunities ETFAUM: 74.30M
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M

News

latest 14 of 206
  • Milestone's Cardamist Launch Faces Its Pricing Test As Coverage Tops 50% And Shares Slide (Earnings Whispers) -10.36% +10.15%
  • Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.30%
  • Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026 (GlobeNewswire)
  • New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation (GlobeNewswire)
  • Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences (GlobeNewswire)
  • Loading…
  • Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial (GlobeNewswire) +7.43%
  • Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR (GlobeNewswire) -7.78%
  • Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States (GlobeNewswire)
  • Milestone Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
  • Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes (GlobeNewswire)
  • Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial (InvestorsHub)
  • Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) (GlobeNewswire)
  • Milestone Pharmaceuticals shares tumble after Q2 earnings miss (InvestorsHub) -11.42%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-13--0.216--1.007
2026Q22026-08-12-0.210-0.195-0.2100.560.826
2026Q12026-05-13-0.2000.190-0.2000.2430.126
2025Q42026-03-20-0.160-0.160-0.1641.510.005
2025Q32025-11-12-0.120-0.164-0.1240.000.005
2025Q22025-08-12-0.200-0.178-0.1950.000.004
2025Q12025-05-14-0.310-0.185-0.3130.000.004
2024Q42025-03-13-0.190-0.156-0.2320.000.005
2024Q32024-11-12-0.140-0.163-0.1430.000.004
2024Q22024-08-08-0.140-0.190-0.1420.000.004
2024Q12024-05-13-0.210-0.260-0.2060.000.004
2023Q42024-03-21-0.320-0.313-0.4070.000.004
2023Q32023-11-13-0.350-0.382-0.3510.000.005
2023Q22023-08-10-0.370-0.386-0.3740.000.005
2023Q12023-05-11-0.350-0.398-0.3491.000.005
2022Q42023-03-29-0.310-0.335-0.3083.501.174

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3.500-3.053-3.4990.000.00
2020FY-1.700-1.946-1.7030.000.00
2021FY-1.020-1.060-1.02415.0015.00
2022FY-1.380-1.425-1.3755.002.00
2023FY-1.390-1.370-1.3891.001.00
2024FY-0.670-0.628-0.6670.000.00
2025FY-0.750-0.716-0.7501.550.00
2026FY--0.844--3.43
2027FY--0.804--19.61
2028FY--0.318--102.86
2029FY-0.046--180.88
2030FY-0.362--256.1

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-267011.000.801.50
2026Q3S2026-10-197151.000.801.50
2026Q3S2026-08-197141.140.802.00
2026Q3S2026-08-126141.200.902.00
2026Q3S2026-07-276021.560.502.00
2026Q3S2026-07-216131.560.502.00
2026Q3S2026-07-166121.730.503.00
2026Q3S2026-06-036112.061.003.00
2026Q3S2026-05-136212.061.003.00
2026Q3S2026-04-086112.261.003.30
2026Q3S2026-03-205112.311.003.30
2026Q3S2026-02-254102.531.803.30
2026Q3S2026-01-264202.531.803.30
2026Q3S2026-01-234212.531.803.30

Estimate history

EPS, annual-0.342-0.98-3.499-1.703-1.024-1.375-1.389-0.667-0.752-0.6938
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.142-0.143-0.232-0.313-0.195-0.124-0.164-0.2-0.206
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000155101.5462.34
Period201720182019202020212022202320242025TTM
Sales, quarterly0000001.5460.2380.559
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual23.64823.64824.50629.82829.89834.28633.48353.354106.236124.498
Period201720182019202020212022202320242025MRQ
Shares, quarterly53.2753.32853.35453.46453.49485.169106.236117.794124.498
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2.341.550.001.005.0015.000.000.000.00
Cost of Goods Sold Incl. D&A0.220.110.650.600.48-0.380.240.01
Gross Profit2.121.43-0.650.404.52--0.38-0.24-0.01
Selling, General and Administrative Excl. Other80.8763.9241.7261.8164.6258.1750.7158.0424.07
Research and Development16.5918.4514.6231.2740.2039.0434.7642.3417.10
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-78.75-62.48-42.36-61.41-60.10-43.53-51.08-58.27-24.08
Interest Expense10.813.843.582.550.00---0.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-84.38-63.40-41.78-60.00-58.84-43.31-50.36-55.68-23.37
Income Taxes-0.37-0.35-0.26-0.31-0.46-0.46-0.39-0.45-0.18
Consolidated Net Income-84.01-63.06-41.52-59.69-58.39-42.85-49.97-55.23-23.19
Net Income From Continuing Operations-84.01-63.06-41.52-59.69-58.39-42.85-49.97-55.23-23.19
Net Income-84.01-63.06-41.52-59.69-58.39-42.85-49.97-55.23-23.19
EPS (Recurring)-0.61-0.75-0.67-1.39-1.38-1.02-1.70-3.50-0.98
EPS (Basic, Before Extraordinaries)-0.69-0.75-0.67-1.39-1.38-1.02-1.70-3.50-0.98
EPS (Diluted)-0.69-0.75-0.67-1.39-1.38-1.02-1.70-3.50-0.98
EBITDA-78.57-62.37-41.72-60.81-59.62-43.17-50.71-58.04-24.07
Non-Operating Income (Expense)5.182.924.163.971.250.220.732.600.71
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.427.465.789.539.055.350.000.880.47
Price To Sales Ratio79.32109.60-71.7433.6218.27---
Gross Margin90.7092.63-40.2090.40----
Operating Margin-3,360.86-4,041.72--6,141.00-1,201.96-290.21---
Net Margin-3,585.62-4,078.78--5,968.50-1,167.76-285.69---
Shares Outstanding124.50106.2453.3533.4834.2929.9029.8324.5123.65
Market Capitalization82.4482.44125.8555.92135.77195.66199.81392.13380.38

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.560.241.550.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.090.070.030.030.030.030.570.03
Gross Profit0.470.171.51-0.03-0.03-0.03-0.57-0.03
Selling, General and Administrative Excl. Other26.1923.9418.8611.8812.5920.5911.859.65
Research and Development3.603.365.624.013.755.074.014.02
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-25.72-23.77-17.35-11.90-12.62-20.62-12.41-9.68
Interest Expense4.734.140.990.970.950.940.920.90
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-28.70-26.18-17.50-12.00-13.05-20.85-12.43-9.50
Income Taxes-0.09-0.11-0.09-0.07-0.09-0.09-0.07-0.06
Consolidated Net Income-28.61-26.07-17.41-11.92-12.97-20.76-12.36-9.44
Net Income From Continuing Operations-28.61-26.07-17.41-11.92-12.97-20.76-12.36-9.44
Net Income-28.61-26.07-17.41-11.92-12.97-20.76-12.36-9.44
EPS (Recurring)-0.21-0.20-0.16-0.12-0.20-0.31-0.23-0.14
EPS (Basic, Before Extraordinaries)-0.21-0.20-0.16-0.12-0.20-0.31-0.23-0.14
EPS (Diluted)-0.21-0.20-0.16-0.12-0.20-0.31-0.23-0.14
EBITDA-25.66-23.72-17.32-11.88-12.59-20.59-11.85-9.65
Non-Operating Income (Expense)1.741.730.830.870.520.700.901.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.341.283.551.251.311.351.471.40
Price To Sales Ratio79.3286.91138.81-----
Gross Margin84.0870.5997.80-----
Operating Margin-4,601.07-9,988.24-1,122.32-----
Net Margin-5,118.78-10,952.10-1,126.07-----
Shares Outstanding124.50117.79106.2485.1753.4953.4653.3553.33
Market Capitalization82.44140.02172.04169.99103.7242.69125.8580.97

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments105.9669.6966.0064.58114.14142.31119.8285.9826.91
Short Term Receivables3.512.393.851.210.480.950.840.680.54
Inventories0.650.000.000.000.000.000.000.000.00
Other Current Assets1.801.843.186.004.305.431.841.400.10
Total Current Assets111.9273.9373.0371.80118.92148.69122.5088.0527.55
Net Property, Plant & Equipment1.641.572.192.680.931.290.930.030.04
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets113.5675.5075.2374.48119.85149.97123.4388.0827.59
Short Term Debt Incl. Current Port. of LT Debt0.650.570.550.490.220.240.330.000.00
Accounts Payable5.641.933.982.264.380.000.000.000.00
Income Tax Payable------0.000.060.00
Other Current Liabilities7.695.622.703.382.175.918.004.481.60
Total Current Liabilities13.988.137.236.146.786.168.334.531.60
Long Term Debt57.7354.2351.232.000.470.700.180.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.080.000.000.000.000.000.000.000.00
Total Liabilities71.7962.3558.458.137.256.868.514.531.60
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00138.7659.10
Common Equity41.7713.1516.7766.35112.60143.12114.92-55.21-33.12
Total Shareholders Equity41.7713.1516.7766.35112.60143.12114.9283.5525.98
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity41.7713.1516.7766.35112.60143.12114.9283.5525.98
Total Liabilities & Stockholders Equity113.5675.5075.2374.48119.85149.97123.4388.0827.59
Book Value Per Share0.390.250.501.943.774.804.69-2.33-1.40
Tangible Book Value Per Share0.390.250.501.943.774.804.69-2.33-1.40
Full-Time Employees3833473929283023-
Price to Book Ratio4.535.241.961.561.741.403.412.86-
Return on Assets-66.71-55.09-79.73-60.09-31.76-36.55-52.22-40.09-
Return on Equity-229.65-277.55-143.61-65.26-33.52-38.73-55.66-42.33-
Return on Invested Capital-63.38-61.63-87.77-85.43-37.90-34.74-47.98-27.75-31.12
Quick Ratio7.969.1010.1111.7017.5524.1414.7119.4217.17
Current Ratio8.019.1010.1111.7017.5524.1414.7119.4217.17

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-83.29-63.06-41.52-59.69-58.39-42.85-49.97-55.23-23.19
Depreciation0.170.110.110.090.090.090.100.040.01
Other Funds (Non Cash)18.1211.228.9111.939.097.284.951.190.63
Funds from Operations-65.00-51.73-32.50-47.67-49.21-35.48-44.93-54.00-22.54
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.262.683.661.24-3.262.26-5.812.851.50
Income Taxes Payable------0.00-0.060.05
Cash from Operating Activities-60.75-49.04-28.85-46.42-52.47-33.22-50.73-51.15-21.05
Capital Expenditures-0.36-0.30-0.03-0.11-0.270.000.00-0.41-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-0.8611.558.324.87-56.8570.00-70.000.0316.00
Purchase of Investments-161.75-82.92-113.55-137.13-85.85-15.00-90.00-35.00-3.03
Sale Or Maturity of Investments160.8994.47121.87142.0029.0085.0020.0035.0319.03
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-1.2111.258.284.76-57.1270.00-70.00-0.3816.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock113.9085.5332.120.573.095.0673.2285.4180.12
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock113.9085.5332.120.573.095.0673.2285.4180.12
Proceedsfrom Stock Options48.5537.5927.450.392.630.0024.9285.3679.65
Issuance or Reduction of Debt, Net74.650.000.0047.220.000.000.000.000.00
Change in Long Term Debt74.650.000.0047.220.000.000.000.000.00
Issuance of Long Term Debt74.650.000.0047.220.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.020.000.000.000.000.000.000.000.00
Other Financing Activities Uses-0.020.000.000.000.000.000.000.000.00
Cash from Financing Activities188.5385.5332.1247.793.095.0673.2285.4180.12
Net Change in Cash126.5847.7311.556.12-106.5141.83-47.5133.8775.07
Free Cash Flow-61.10-49.34-28.88-46.54-52.74-33.22-50.73-51.56-21.05
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments170.61184.22105.9682.5843.4255.96
Short Term Receivables3.965.003.511.512.002.16
Inventories4.721.830.650.000.000.00
Other Current Assets1.031.211.802.580.752.36
Total Current Assets180.33192.25111.9286.6746.1760.48
Net Property, Plant & Equipment1.301.481.641.081.251.41
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets181.62193.73113.5687.7547.4261.88
Short Term Debt Incl. Current Port. of LT Debt0.670.660.650.480.520.54
Accounts Payable8.4510.025.643.182.932.38
Other Current Liabilities13.0610.267.696.865.8410.04
Total Current Liabilities22.1820.9413.9810.529.2812.96
Long Term Debt141.16136.6757.7356.7355.8855.05
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.060.070.080.000.000.00
Total Liabilities163.41157.6971.7967.2565.1668.01
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity18.2236.0541.7720.50-17.75-6.12
Total Shareholders Equity18.2236.0541.7720.50-17.75-6.12
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity18.2236.0541.7720.50-17.75-6.12
Total Liabilities & Stockholders Equity181.62193.73113.5687.7547.4261.88
Book Value Per Share0.150.310.390.24-0.33-0.11
Tangible Book Value Per Share0.150.310.390.24-0.33-0.11
Full-Time Employees--38---
Price to Book Ratio4.533.038.39-6.03-16.943.25
Return on Assets-73.36-53.49-66.71-68.07-81.27-65.78
Return on Equity-35,522.62-456.88-229.65-260.65-780.29-307.27
Return on Invested Capital-17.95-15.09-17.50-15.44-34.00-42.44
Quick Ratio7.929.097.968.244.974.67
Current Ratio8.139.188.018.244.974.67

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-28.36-26.07-16.84-12.03-13.56-20.76
Depreciation0.060.060.030.030.030.03
Other Funds (Non Cash)6.005.424.462.242.342.21
Funds from Operations-22.30-20.59-12.35-9.76-11.19-18.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.244.540.03-0.08-1.844.58
Cash from Operating Activities-22.53-16.05-12.32-9.84-13.03-13.95
Capital Expenditures-0.03-0.05-0.28-0.00-0.01-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments111.87-79.992.88-35.6210.7233.59
Purchase of Investments0.39-79.99-46.64-35.52-0.06-0.88
Sale Or Maturity of Investments111.480.0049.52-0.1010.7834.47
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities111.84-80.032.60-35.6210.7133.58
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock9.0119.3735.8649.670.040.14
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.0119.3735.8649.670.040.14
Proceedsfrom Stock Options-0.0511.0713.8723.660.000.14
Issuance or Reduction of Debt, Net-0.3575.000.000.000.000.00
Change in Long Term Debt-0.3575.000.000.000.000.00
Issuance of Long Term Debt-0.3575.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.01-0.010.000.000.000.00
Other Financing Activities Uses-0.01-0.010.000.000.000.00
Cash from Financing Activities8.6594.3535.8649.670.040.14
Net Change in Cash97.96-1.7326.134.21-2.2819.77
Free Cash Flow-22.56-16.10-12.60-9.84-13.04-13.96

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.29%19.9M122.1M1.35M
2026-10-1516.14%19.7M122.1M1.42M
2026-09-3015.57%19.0M122.1M1.43M
2026-09-1515.04%18.4M122.1M1.51M
2026-08-3114.22%17.4M122.1M1.42M
2026-08-1413.63%16.6M122.1M1.38M
2026-07-3112.71%15.7M123.4M1.37M
2026-07-1511.82%14.6M123.4M1.39M
2026-06-3010.21%12.6M123.4M1.85M
2026-06-158.60%10.6M123.4M1.99M
2026-05-297.45%9.2M123.3M2.01M
2026-05-156.07%7.5M123.2M2.05M
2026-04-306.71%7.8M116.5M2.10M
2026-04-158.87%10.3M116.5M2.25M
2026-03-317.29%8.5M116.0M2.28M
2026-03-137.55%8.8M116.0M4.09M
2026-02-2710.04%8.4M83.9M4.93M
2026-02-138.91%7.5M83.9M5.34M
2026-01-3011.89%9.6M80.7M5.28M
2026-01-1511.58%9.4M81.1M5.12M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.001.000.250.0001,4960.000.864-0.0150.000
call1.000.000.100.084.4841380.000.416-0.0100.000
call1.500.000.100.035.9262250.000.360-0.0120.000
call2.000.000.250.007.1350.000.000.336-0.0150.000
call2.500.002.000.007.5220.000.000.322-0.0150.000
call5.000.002.150.009.6510.000.000.289-0.0190.000
call7.500.002.150.0010.6650.000.000.277-0.0210.000
put0.500.000.300.0011.4220.000.00-0.139-0.0140.000
put1.000.001.000.460.00014.000.00-0.584-0.0090.000
put1.500.351.350.5817.4320.000.00-0.640-0.0120.000
put2.000.901.900.0019.0470.000.00-0.664-0.0150.000
put2.500.204.000.000.0000.000.00-0.678-0.0160.000
put5.002.206.500.000.0000.000.00-0.711-0.0190.000
put7.504.709.000.000.0000.000.00-0.723-0.0200.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-288-KCurrent report2026-10-23SEC
2026-09-038-KCurrent report2026-09-03SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-07SCHEDULE 13GSEC
2026-06-158-KCurrent report2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-05-22EFFECTEffectiveness filing by commission orderSEC
2026-05-20CORRESPSEC
2026-05-18UPLOADUpload SubmissionSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-13S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-13SCHEDULE 13G/ASEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-10SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-04-16144Filing for proposed sale of securities under Rule 144.SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-233Initial statement of beneficial ownership of securities2026-03-17SEC
2026-03-208-KCurrent report2026-03-20SEC
2026-03-2010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040082.49K1
2026-030000
2026-020000
2026-0100256.98K7
2025-1200836.69K5
2025-110000

Institutional holders

Manager% owned
Pavaki Capital Management LLC7.50%
RTW INVESTMENTS, LP6.29%
Propel Bio Management, LLC5.97%
Point72 Asset Management, L.P.4.35%
Simplify Asset Management Inc.2.69%
MILLENNIUM MANAGEMENT LLC2.52%
Kalehua Capital Management LLC2.04%
TWO SIGMA INVESTMENTS, LP1.64%
MARSHALL WACE, LLP1.44%
RVW Wealth, LLC0.92%

Funds

Fund% owned
Simplify Propel Opportunities ETF2.69%
Invesco NASDAQ Future Gen 200 ETF0.04%
Fidelity Nasdaq Composite Index Fund0.03%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF0.02%
Blackstone Alternative Multi-Strategy Fund0.01%

OakChart. MIST. Cached 15 minutes.